HANA RECEIVES ORPHAN DRUG DESIGNATION FOR ROPIDOXURIDINE

Hana Biosciences has announced that the FDA has granted orphan drug designation for ropidoxuridine (IPdR) for the treatment of malignant glioma, which makes up approximately half of all primary brain tumors.

Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.